⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BIIB News
Biogen Inc. Common Stock
Boehringer Ingelheim en Simcere werken samen aan een dubbeldoelgerichte antilichaambehandeling om tegemoet te komen aan onvervulde behoeften bij inflammatoire darmziekten USA - Nederlands USA - English USA - English USA - Français
prnewswire.com
BIIB
Boehringer Ingelheim et Simcere s'associent pour développer un traitement par anticorps à double cible afin de répondre aux besoins non satisfaits dans le domaine des maladies inflammatoires chroniques de l'intestin USA - Français USA - English USA -
prnewswire.com
BIIB
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease USA - English USA - English
prnewswire.com
BIIB
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
globenewswire.com
BIIB
RET Fusion Targeted Therapies Market Set for Robust Growth by 2034 Amid Precision Oncology Shift | DelveInsight
prnewswire.com
MRK
LLY
RIGL
AZN
GILD
ABBV
PFE
TMO
BMY
NVS
BIIB
Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)
prnewswire.com
BIIB
サムスンエピスホールディングス、2025年度第4四半期および通期決算を発表
businesswire.com
AMGN
REGN
JNJ
BIIB
Samsung Epis Holdings公布2025年第四季度及财年财务业绩
businesswire.com
AMGN
REGN
JNJ
BIIB
Samsung Epis Holdings meldet Finanzergebnisse für das vierte Quartal und das Geschäftsjahr 2025
businesswire.com
AMGN
BIIB
GEN
JNJ
REGN
Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results
businesswire.com
AMGN
JNJ
REGN
BIIB